[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Kim DW, Jo YH, Kim JH, Wu HG, Rhee CS, Lee CH, Kim TY, Heo DS, Bang YJ, Kim NK: Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer; 2004 Nov 15;101(10):2257-60
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
  • BACKGROUND: The optimal chemotherapy regimen for the treatment of olfactory neuroblastoma has not been clearly defined.
  • The purpose of the current study was to evaluate the efficacy of neoadjuvant chemotherapy with the combination of etoposide, ifosfamide, and cisplatin (VIP) for patients with olfactory neuroblastoma.
  • METHODS: Eleven consecutive patients with newly diagnosed olfactory neuroblastoma were treated with etoposide (75 mg/m2), ifosfamide (1000 mg/m2), and cisplatin (20 mg/m2) all administered intravenously on Days 1-5.
  • All toxic events were reversible, and no chemotherapy-related deaths were documented.
  • CONCLUSIONS: Neoadjuvant VIP chemotherapy was active in the treatment of olfactory neuroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esthesioneuroblastoma, Olfactory / drug therapy. Nasal Cavity / pathology. Neoadjuvant Therapy. Nose Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • (PMID = 15484215.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Koo BK, An JH, Jeon KH, Choi SH, Cho YM, Jang HC, Chung JH, Lee CH, Lim S: Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review. Endocr J; 2008 Jul;55(3):469-75
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review.
  • Olfactory neuroblastomas are rare, slow-growing malignant tumors, usually diagnosed at advanced stages.
  • Ectopic adrenocorticotropic hormone (ACTH) syndrome caused by an olfactory neuroblastoma is extremely rare.
  • We reported two Korean women who suffered from ectopic ACTH syndrome (EAS) caused by olfactory neuroblastomas.
  • The first patient was a 66-year-old woman who had been diagnosed as olfactory neuroblastoma and refused the management two years before and the second patient was a 37-year-old woman on chemotherapy for olfactory neuroblastoma.
  • ACTH secretion by the tissue was confirmed by immunohistochemistry.
  • By contrast, the second patient presented as severe pneumonia caused by cytomegalovirus and was treated with anti-viral agent followed by chemotherapy and radiotherapy, and her residual mass remained.
  • However, after treatment, both patients' plasma ACTH and cortisol levels returned to normal without any adrenolytic therapy.
  • [MeSH-major] ACTH Syndrome, Ectopic / radiography. Esthesioneuroblastoma, Olfactory / secretion. Nasal Cavity / radiography. Nose Neoplasms / secretion

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469486.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 36
  •  go-up   go-down


3. Mintzer DM, Zheng S, Nagamine M, Newman J, Benito M: Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital. Oncologist; 2010;15(1):51-8
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Adrenocorticotropic Hormone / metabolism. Esthesioneuroblastoma, Olfactory / secretion. Esthesioneuroblastoma, Olfactory / therapy. Nose Neoplasms / secretion. Nose Neoplasms / therapy
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antifungal Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Hydrocortisone / blood. Hydrocortisone / therapeutic use. Immunohistochemistry. Ketoconazole / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Cavity. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4955-62 [15914534.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):371-7 [16303835.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • [Cites] Otolaryngol Pol. 2006;60(6):849-58 [17357662.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):885-91 [18189294.001]
  • [Cites] Endocr J. 2008 Jul;55(3):469-75 [18469486.001]
  • [Cites] Neurosurgery. 2008 Jul;63(1 Suppl 1):ONS44-52; discussion ONS52-3 [18728603.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):201-4 [18633576.001]
  • [Cites] Head Neck. 2008 Dec;30(12):1607-14 [18798301.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):357-8 [11773199.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] J Endocrinol Invest. 2003 Aug;26(8):710-7 [14669823.001]
  • [Cites] Endocr Pract. 2004 Mar-Apr;10(2):119-24 [15256328.001]
  • [Cites] Arch Otolaryngol. 1977 Sep;103(9):514-7 [332133.001]
  • [Cites] Ann Pathol. 1987;7(2):137-42 [3620028.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):61-8 [8191648.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):35-43 [8583243.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1038-43 [8577710.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):129-31 [8769407.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1193-202 [10199752.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):73-5 [15527110.001]
  • [Cites] Endocr J. 2005 Dec;52(6):675-81 [16410658.001]
  • (PMID = 20053760.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9002-60-2 / Adrenocorticotropic Hormone; R9400W927I / Ketoconazole; RWM8CCW8GP / Octreotide; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC3227887
  •  go-up   go-down


Advertisement
4. Weinreb I, Perez-Ordoñez B: Non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. Report of 2 cases and review of the literature. Head Neck Pathol; 2007 Sep;1(1):21-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first had a tumor involving left ethmoid sinus and nasal cavity and the second, a neoplasm involving nasopharynx, sphenoid sinus, with bilateral involvement of cavernous sinuses.
  • The second is alive with locally advanced disease 7 years after radiotherapy and chemotherapy.
  • Other cases do not show specific features and are probably best regarded as "neuroendocrine carcinoma, NOS".
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Nasal Cavity / pathology. Nasopharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Jul;27(1):79-82 [7557912.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):826-32 [9712424.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e3 [16119901.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):562-9 [6091074.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1617-22 [11037813.001]
  • [Cites] Rhinology. 2001 Mar;39(1):52-4 [11340699.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):330-9 [6243246.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2388-405 [7139532.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • (PMID = 20614276.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807510
  • [Keywords] NOTNLM ; Carcinoid tumor / Nasal cavity / Neuroendocrine carcinoma / Olfactory neuroblastoma / Paranasal sinuses / Small cell carcinoma
  •  go-up   go-down


5. Kim JW, Kong IG, Lee CH, Kim DY, Rhee CS, Min YG, Kim CW, Chung JH: Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival. Otolaryngol Head Neck Surg; 2008 Nov;139(5):708-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival.
  • OBJECTIVE: This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB).
  • Of seven patients who were treated with neoadjuvant chemotherapy, one patient with diffuse bcl-2 expression achieved complete remission.
  • Another patient without bcl-2 expression had no response to chemotherapy.
  • CONCLUSION: Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / metabolism. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / metabolism. Nose Neoplasms / therapy. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 2.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984268.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


6. Pino Rivero V, Trinidad Ruíz G, González Palomino A, Pardo Romero G, Pantoja Hernández CG, Marcos García M, Montero García C, Blasco Huelva A: [Olfactory neuroblastoma in an old patient. Report of a case]. An Otorrinolaringol Ibero Am; 2005;32(5):429-35
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma in an old patient. Report of a case].
  • [Transliterated title] Neuroblastoma olfatorio en paciente de edad avanzada. Presentación de un caso.
  • Olfactory neuroblastoma or esthesioneuroblastoma is a rare embrionary tumor, much more in old patients, which uses to present as a pollipoid mass with nasal obstruction, epistaxis and anosmia of long evolution.
  • We report the case of a 82-year-old male with such symptoms diagnosed by biopsy as neuroblastoma class III according the histologic Hyams grading.
  • Due to the age of the patient and grade of the tumor we did not perform surgery and, although a chemotherapy-radiotherapy treatment was suggested, the patient was not agree with it and he has not been attended or followed in our consulting rooms.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiography. Nasal Cavity / radiography. Nose Neoplasms / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318085.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Cohen ZR, Marmor E, Fuller GN, DeMonte F: Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus; 2002 May 15;12(5):e3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Misdiagnosis of olfactory neuroblastoma.
  • OBJECT: Olfactory neuroblastoma (ON) is a rare neoplasm arising from the olfactory epithelium and found in the upper nasal cavity.
  • Based on the belief that misdiagnosis commonly occurs, they emphasized the importance of establishing the correct diagnosis, because the treatment regimens and prognosis of these tumor types are often significantly different.
  • METHODS: Twelve consecutive patients in whom ON was diagnosed were referred to the Department of Neurosurgery at the M. D.
  • Demographic data were collected, physical findings and mode of treatments were documented, and neuroimaging studies were assessed.
  • Only in two of 12 patients was the diagnosis of ON confirmed.
  • Eight of 10 patients in whom lesions were misdiagnosed required significant alteration in the initially proposed treatment plan.
  • The correct diagnosis should be ensured before initiating treatment to provide the optimum therapy and spare the patients from needless and potentially toxic treatment.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Diagnostic Errors. Esthesioneuroblastoma, Olfactory / diagnosis. Melanoma / diagnosis. Nasal Cavity. Nose Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blindness / etiology. Case Management. Cisplatin / administration & dosage. Cisplatin / adverse effects. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Ethmoid Sinus / pathology. Humans. Hypopituitarism / etiology. Iatrogenic Disease. Male. Middle Aged. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Radiation Injuries / etiology. Radiotherapy / adverse effects. Retrospective Studies. Sphenoid Sinus / pathology. Vincristine / administration & dosage. Vincristine / adverse effects


8. Jarzabski A, Kawecki A, Jagielska B: [Olfactory neuroblastoma: own experiences]. Otolaryngol Pol; 2000;54 Suppl 31:94-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma: own experiences].
  • [Transliterated title] Olfactory neuroblastoma--doświadczenie własne.
  • The authors present material of 12 cases olfactory neuroblastoma observed in Head and Neck Department of Cancer Center in Warsaw from 1961 to 1998.
  • Six patients in stage C were treated also with surgery, radiotherapy and chemotherapy.
  • One patient died from olfactory neuroblastoma, two other were died from other reasons.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974854.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


9. Kano S, Furuta Y, Homma A, Oridate N, Higuchi E, Suzuki F, Nagahashi T, Sawamura Y, Fukuda S: [Olfactory neuroblastoma: the Hokkaido University experience]. Nihon Jibiinkoka Gakkai Kaiho; 2006 May;109(5):433-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma: the Hokkaido University experience].
  • Olfactory neuroblastoma is such a rare malignancy that no consensus has been reached on its management.
  • We analyzed 17 patients with olfactory neuroblastoma treated between April 1980 and March 2004--9 men and 8 women, aged 16 to 76 years old(mean: 50.4 years).
  • Initially, 2 were treated with surgery alone, 5 with surgery and radiotherapy, and 2 with a combination of these and chemotherapy.
  • Without surgery, radiotherapy alone was conducted in 3 and combined of radiation and chemotherapy in 5.
  • Three of the 5 patients treated with surgery and radiotherapy survive without locoregional recurrence as do 2 with chemotherapy added.
  • Combined radiotherapy and chemotherapy without surgery was effective in 2.
  • In conclusion, combined craniofacial resection plus radiotherapy and chemotherapy seemed to improve survival.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Hospitals, University / statistics & numerical data. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Salvage Therapy. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768158.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Woźniak MA, Dobrzyński P, Gutowska A: [Olfactory neuroblastoma in 55 year old woman]. Pol Merkur Lekarski; 2005 Sep;19(111):440-1
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma in 55 year old woman].
  • In this article the authors describe a rare case of olfactory neuroblastoma in a 55-year-old woman surgically treated because of nasal polyposis.
  • Three years earlier she had been operated for nasal polyposis on the same side in another ENT department.
  • In histopathological examination it was confirmed to be olfactory neuroblastoma.
  • The tumor was classified as stage B in Kadish classification of olfactory neuroblastoma.
  • The histopathologic diagnosis and CT scan made after the surgery resulted in necessity of further oncological treatment.
  • The olfactory neuroblastoma is rare, difficult to diagnose, malignant, slowly growing tumor arising from the olfactory epithelium in the upper nasal cavity.
  • The treatment includes surgery, radiotherapy and chemotherapy.
  • Another objective of this paper is to point out that histopathological examination is crucial in each surgically removed tissue.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Polyps. Nose Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358902.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


11. Constantinidis J, Steinhart H, Koch M, Buchfelder M, Schaenzer A, Weidenbecher M, Iro H: Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000. Otolaryngol Head Neck Surg; 2004 May;130(5):567-74
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma: the University of Erlangen-Nuremberg experience 1975-2000.
  • OBJECTIVE: Olfactory neuroblastoma constitutes a rare and, in clinical terms, biologically variable tumor of the nasal cavity, paranasal sinuses, and the base of the skull and presents a challenge to a modern multidisciplinary therapy.
  • Generally acknowledged prognostic factors and a standard therapy fail to exist.
  • METHODS: Between 1975 and 2000 we diagnosed and treated 26 patients with an olfactory neuroblastoma.
  • Surgical therapy was performed on 23 patients (88.5%), surgery being the exclusive form of therapy (monotherapy) in 5 of these patients.
  • Combined therapy was carried out in 18 cases (surgery, radiotherapy, chemotherapy).
  • Seven (26.9%) of the overall group of treated patients developed a recurrence.
  • Salvage therapy was successful in 60% (3 of 5 patients).
  • Fifteen-year survival following salvage therapy amounts to 60%.
  • CONCLUSIONS: The therapy of olfactory neuroblastoma calls for an interdisciplinary multimodal therapeutic strategy, particularly in the case of advanced tumors.
  • Aggressive salvage therapy can lead to a distinct improvement of long-term survival.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity / pathology. Nose Neoplasms / pathology. Nose Neoplasms / therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15138422.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Strek P, Zagólski O, Składzień J, Przeklasa R, Blaschke J, Białas M, Urbanik A: [Olfactory neuroblastoma removed under endoscopic guidance]. Otolaryngol Pol; 2006;60(3):433-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma removed under endoscopic guidance].
  • INTRODUCTION: Olfactory neuroblastoma is a rare tumour associated with high rates of recurrence and mortality.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • During surgery, a 5 mm in diameter tumour was identified in the left superior nasal meatus.
  • On histopathological examination the diagnosis of esthesioneuroblastoma was established and confirmed by immunohistochemistry.
  • MR scans performed two months later disclosed pathological tissues in the left ethmoid region.
  • CONCLUSIONS: The exclusively surgical treatment proved effective due to early stage of the tumour and no evidence of infiltration of the frontal skull base.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Endoscopy. Ethmoid Sinusitis / etiology. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989461.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


13. Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T: [Olfactory neuroblastoma with spinal metastasis: case report]. No Shinkei Geka; 2007 May;35(5):503-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma with spinal metastasis: case report].
  • Olfactory neuroblastoma is a rare tumor of the nasal cavity.
  • We report a case of olfactory neuroblastoma with cauda equina metastases.
  • A 49-year old male had undergone surgery twice previously; the first for olfactory neuroblastoma in October, 1990, and the second for its intracranial and orbital metastasis in September, 1999.
  • The mass was partially removed and histologically diagnosed as olfactory neuroblastoma metastasis.
  • Whole-spine irradiation of 32 Gy and lumber-spine irradiation of 10 Gy were performed.
  • Olfactory neuroblastoma with spinal metastasis is rare and only 11 cases have been reported in the literature.
  • A very poor prognosis was observed in the patients of olfactory neuroblastoma with spinal metastasis.
  • Olfactory neuroblastoma is a radiosensitive tumor, and radiotherapy for spinal metastasis was reported to be effective.
  • However, effectiveness of chemotherapy was still uncertain.
  • The patient with olfactory neuroblastoma should be observed carefully even though no local recurrence had been detected over 10 years.
  • Radiotherapy and further treatment including chemotherapy should be considered in case of spinal metastasis.
  • [MeSH-major] Cauda Equina. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491347.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Zhang LW, Zhang MS, Qi J, Zhang JT, Li GL, Luo L, Wang ZC: Management of intracranial invasive olfactory neuroblastoma. Chin Med J (Engl); 2007 Feb 5;120(3):224-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of intracranial invasive olfactory neuroblastoma.
  • BACKGROUND: Olfactory neuroblastoma (ONB) is a rare tumor that often arise from the nasal cavity.
  • The aim of this study was to investigate the clinical characteristics and treatments of intracranial invasive ONB.
  • Their clinical features, radiological and pathological characteristics, and surgical treatments were analyzed.
  • After the operation, all the patients received radiotherapy, and one received chemotherapy.
  • In all the patients, nasal obstruction was alleviated without cerebrospinal fluid leakage.
  • [MeSH-major] Brain Neoplasms / surgery. Esthesioneuroblastoma, Olfactory / surgery
  • [MeSH-minor] Adolescent. Adult. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17355826.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Park KJ, Kang SH, Lee HG, Chung YG: Olfactory neuroblastoma following treatment for pituitary adenoma. J Neurooncol; 2008 Nov;90(2):237-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma following treatment for pituitary adenoma.
  • Olfactory neuroblastoma is extremely rare as a second neoplasm.
  • We report an unusual case of olfactory neuroblastoma in a 59-year-old woman who had undergone two operations and received 54 Gy of irradiation for pituitary adenoma 20 years ago.
  • At the time of admission, the patient presented with nasal obstruction and frequent epistaxis.
  • Imaging studies showed a large mass in the nasal cavities and ethmoid sinus, extending to the intracranial area, with no evidence of any recurrence of the previous pituitary adenoma.
  • The tumor was completely excised via a trans-cranial and trans-nasal approach.
  • A diagnosis of olfactory neuroblastoma was established, and the patient was given postoperative chemotherapy.
  • Although relatively uncommon, second neoplasms are an important consideration in the differential diagnosis of patients with new or recurring symptoms after treatment for pituitary adenoma.
  • Furthermore, it is likely that radiation played a critical role in the development of olfactory neuroblastoma in our patient.
  • [MeSH-major] Adenoma / radiotherapy. Esthesioneuroblastoma, Olfactory / etiology. Neoplasms, Second Primary / etiology. Nose Neoplasms / etiology. Pituitary Neoplasms / radiotherapy. Radiotherapy / adverse effects
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging / methods. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / radiation effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72 [12915637.001]
  • [Cites] Oncology. 1990;47(2):199-205 [1969134.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Arch Pathol. 1972 Jan;93(1):26-31 [5006996.001]
  • [Cites] Neurosurg Focus. 2007;23(3):E7 [17961019.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] J Neurosurg. 1981 Oct;55(4):615-9 [7277008.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):230-9 [17047388.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):459-63 [11594709.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:69-74 [7841081.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):502-12 [2204689.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):949-55 [1431959.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Neurochirurgia (Stuttg). 1993 Nov;36(6):203-6 [8309496.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):28-31 [8315464.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):854-60 [17599761.001]
  • (PMID = 18679581.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Preusser M, Hutterer M, Sohm M, Koperek O, Elandt K, Dieckmann K, Prayer D, Marosi C: Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol; 2010 Apr;97(2):305-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.
  • Olfactory neuroblastoma (esthesioneuroblastoma) is a rare neoplasm of the olfactory epithelium in the upper nasal cavity.
  • After exhaustion of all conventional therapeutic options, we initiated treatment with the oral multityrosinekinase inhibitor sunitinib mesylate.
  • Using this drug, significant improvement of clinical symptoms, disease stabilization, and recovery from Karnofsky index of 40% to 70% could be achieved in the absence of significant adverse drug effects.
  • The patient died 15 months after initiation of sunitinib therapy due to complications of a traumatic femoral neck fracture without evidence of tumor progression.
  • Immunohistochemical analysis of tumor tissue specimens obtained at initial surgery revealed ample expression of platelet-derived growth factor receptor (PDGFR)-b on stromal and endothelial cells.
  • Sunitinib should be considered for palliative therapy of advanced esthesioneuroblastoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Esthesioneuroblastoma, Olfactory / drug therapy. Indoles / therapeutic use. Nasal Cavity / pathology. Neoplasm Recurrence, Local / drug therapy. Nose Neoplasms / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2008 Nov;90(2):201-4 [18633576.001]
  • [Cites] Nat Rev Drug Discov. 2006 Apr;5(4):279-80 [16628834.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):885-91 [18189294.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Clin Ther. 2007 Jul;29(7):1338-53 [17825686.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):73-5 [15527110.001]
  • (PMID = 19820899.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  •  go-up   go-down


17. Miura K, Mineta H, Yokota N, Tsutsui Y: Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy. Pathol Int; 2001 Dec;51(12):942-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy.
  • We report a 56-year-old man in whom an olfactory neuroblastoma with epithelial and endocrine differentiation transformed into a mature ganglioneuroma after chemoradiotherapy.
  • A radical craniofacial resection of the primary tumor was performed after 16 Gy of local irradiation and systemic chemotherapy.
  • The biopsy before chemoradiotherapy showed a neuroblastoma with Homer-Wright rosettes, fibrillary matrix, Flexner-Wintersteiner rosettes and antidiuretic hormone production.
  • After chemoradiotherapy, the histology changed to that of a ganglioneuroma consisting of large ganglion cells and Schwann cells without immature neuroblastoma components.
  • Although transformation to ganglioneuroma in an adrenal neuroblastoma is common, an olfactory neuroblastoma showing ganglioneuronal maturation after chemoradiotherapy has not been reported.
  • The pluripotent progenitor cells of the olfactory neurons may be the origin and their existence explains why various neoplasms with neuronal and epithelial differentiation arise from the olfactory mucosa.
  • [MeSH-major] Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / radiation effects. Esthesioneuroblastoma, Olfactory / pathology. Ganglioneuroma / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Humans. Inappropriate ADH Syndrome. Male. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11844067.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Kim HJ, Cho HJ, Kim KS, Lee HS, Kim HJ, Jung E, Yoon JH: Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma. J Craniomaxillofac Surg; 2008 Jan;36(1):47-52
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma.
  • INTRODUCTION: Olfactory neuroblastoma is a very aggressive tumour with high rates of locoregional recurrence and distant metastasis.
  • Therefore, salvage therapy plays an important role in control of these neoplasms.
  • In this study, we present our experience and treatment outcomes for salvage therapy in patients with recurrent olfactory neuroblastoma.
  • MATERIAL AND METHODS: We retrospectively analysed 17 patients treated for advanced olfactory neuroblastoma during the last 15 years.
  • Salvage therapy was performed in 6 of 8 patients with recurrence or metastasis and proved successful in 50% of them.
  • In the patients with locoregional recurrence, the success rate of salvage radiotherapy plus neck dissection was superior to salvage chemotherapy alone.
  • In addition, 17% of the patients with distant metastasis after initial treatment died after salvage therapy.
  • In 15% of patients with a clinical stage N0 at initial diagnosis, nodal recurrence developed and was successfully treated with salvage therapy.
  • CONCLUSION: Complete surgical resection, including craniofacial resection and postoperative radiotherapy without elective neck dissection, is the preferred approach in the treatment of advanced olfactory neuroblastoma.
  • In locoregional recurrence, successful salvage therapy may include selective neck dissection and radiotherapy, but in cases of distant metastasis, the prognosis was poor.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Neoplasm Recurrence, Local / therapy. Nose Neoplasms / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Prognosis. Radiotherapy, High-Energy. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312791.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


19. Tsuchiya D, Kayama T, Kuchiki H, Sato S, Saito S: [A case of olfactory neuroblastoma with intracranial extension and distant metastasis]. No To Shinkei; 2000 Sep;52(9):811-6
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of olfactory neuroblastoma with intracranial extension and distant metastasis].
  • Olfactory neuroblastoma is a rare tumor originating in the upper nasal cavity.
  • We report a clinical case of olfactory neuroblastoma with intracranial extension and distant metastasis.
  • A 35-year-old man complained of nasal stuffiness and bleeding, headache and vomiting.
  • MRI showed a huge mass that occupied the right nasal and paranasal cavities, and extended into the right frontal base.
  • The tumor was removed totally and was histologically diagnosed as olfactory neuroblastoma.
  • About two months after surgery, however, MRI demonstrated a rapid recurrence of the tumor in the nasal and paranasal cavities and the frontal lobe.
  • Chemotherapy was administered using cisplatin and etoposide.
  • Olfactory neuroblastoma is a slow-growing tumor and is highly radiosensitive, but it rarely extends or develops multiple distant metastases and seldom shows a short survival time, as in our case.
  • A review of the literature documented responses in patients treated with a cisplatin-based drug combination.
  • We recommend systemic control using cisplatin-based chemotherapy in addition to irradiation to prevent local recurrence in cases of advanced or metastatic olfactory neuroblastoma.
  • [MeSH-major] Nasal Cavity. Neuroblastoma / pathology. Neuroblastoma / secondary. Nose Neoplasms / pathology. Nose Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064869.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


20. Diaz EM Jr, Johnigan RH 3rd, Pero C, El-Naggar AK, Roberts DB, Barker JL, DeMonte F: Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck; 2005 Feb;27(2):138-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.
  • BACKGROUND: Olfactory neuroblastoma (ONB) is a rare tumor arising from the olfactory neuroepithelium.
  • There is no universally accepted staging system, and treatment approaches lack uniformity.
  • We present one institution's experience with this tumor and the results of therapy.
  • The diagnosis of ONB was histologically confirmed for each patient.
  • In 77% of cases, patients received treatment with surgery followed by postoperative radiation therapy.
  • Sixteen percent received chemotherapy as part of their initial treatment.
  • The mean time for recurrence was 4.67 years.
  • CONCLUSIONS: The M. D.
  • Anderson Cancer Center approach to ONB is complete surgical resection, usually involving a craniofacial approach, with postoperative radiation therapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Academic Medical Centers. Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Texas. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley Periodicals, Inc.
  • (PMID = 15654688.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kim HJ, Kim CH, Lee BJ, Chung YS, Kim JK, Choi YS, Yoon JH: Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma. Auris Nasus Larynx; 2007 Dec;34(4):493-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma.
  • OBJECTIVE: Olfactory neuroblastomas are very aggressive tumors with a high locoregional recurrence rate and distant metastasis.
  • Surgical treatment, including craniofacial resection, has been the main treatment modality, but treatment outcomes of concurrent chemoradiotherapy remain unclear.
  • We present our experiences regarding the treatment outcome of patients with advanced olfactory neuroblastoma undergoing surgical treatment and concurrent chemoradiotherapy.
  • METHODS: We retrospectively analyzed 16 patients treated for advanced olfactory neuroblastoma within the past 10 years.
  • RESULTS: The disease-free 5-year survival rate of the patients (n = 10) who underwent surgical treatment was 68%.
  • In the group having surgical treatment, post-operative radiotherapy and salvage therapy were important to increase the survival rate.
  • CONCLUSION: Complete surgical resection, including craniofacial resection (CFR), and post-operative radiotherapy seem to be essential in the treatment of advanced olfactory neuroblastoma.
  • However, concurrent chemoradiotherapy may be another primary treatment modality.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / drug therapy. Esthesioneuroblastoma, Olfactory / radiotherapy. Nasal Cavity. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Radiotherapy Dosage. Retreatment. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499464.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A: Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):992-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.
  • PURPOSE: To assess the outcome in patients with olfactory neuroblastoma (ONB).
  • All but five patients benefited from RT, and chemotherapy was given in 21 (27%).
  • In univariate analyses, favorable factors were Kadish A or B disease, T1-T3 tumors, no nodal involvement, curative surgery, R0/R1 resection, and RT-dose 54 Gy or higher.
  • Multivariate analysis revealed that the best independent factors predicting the outcome were T1-T3, N0, R0/R1 resection, and total RT dose (54 Gy or higher).
  • CONCLUSION: In this multicenter retrospective study, patients with ONB treated with R0 or R1 surgical resection followed by at least 54-Gy postoperative RT had the best outcome.
  • Novel strategies including concomitant chemotherapy and/or higher dose RT should be prospectively investigated in this rare disease for which local failure remains a problem.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Nasal Cavity / pathology. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20231062.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Shukla RC, Singh PK, Senthil S, Pathak R: Esthesioneuroblastoma: a case report. Nepal Med Coll J; 2010 Jun;12(2):128-32
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma (olfactory neuroblastoma) is an uncommon neuroectodermal tumor.
  • Treatment options consist of surgical resection followed by radiation therapy for primary lesions and the addition of chemotherapy for advanced, recurrent, or metastatic lesions.
  • Patients often present with nasal obstruction, rhinorrhea, recurrent epistaxis, hyposmia, or anosmia.
  • We report a case of esthesioneuroblastoma involving bilateral nasal cavity leading to bilateral nasal obstruction, epistaxis and proptosis of the right eye associated with decreased visual acquity on that eye and loss of smell.
  • A diffuse nontender, 6x6 cms swelling with illdefined margins was seen over the nasal bridge, extending superiorly to glabella and laterally to right maxillary region.
  • X-ray PNS showed soft tissue mass in the nasal cavity with destruction of nasal septum, intense periosteal reaction with destruction of right maxillary wall and extension to right orbit.
  • CT scan of paranasal sinuses showed 8.5 x 4.9 x 7.8 cms irregularly marginated heterogeneous iso- to hyper dense soft tissue mass lesion with extensive adjacent bony destruction and spiculated periosteal reaction involving bilateral nasal cavity and anterior cranial fossa.
  • Biopsy from right nasal mass showed neuroblastoma.
  • The patient received radiotherapy and chemotherapy.
  • The modified Kadish staging system, lymph node status, treatment modality, and age are useful predictors of survival in patients who present with esthesioneuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Nasal Obstruction / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222414.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


24. Kalala L, Focan C, Schils F, Gilles R, Abraham F, Reginster P, Van Den Berge D: [Esthesioneuroblastoma: a case report and literature review]. Rev Med Liege; 2009 Mar;64(3):119-23
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esthesioneuroblastoma (ENB) or olfactive neuroblastoma is a rare cancer arising from the neuroepithelium of the olfactory epithelium of the nasal cavity.
  • The anatomopathological diagnosis will frequently require immuno-histochemical tests and sometimes electron-microscopy as well as genetic testing.
  • Treatment will generally associate debulking or curative surgery (with combined rhino-neurosurgical accesses) and conformal stereo-tactic radiotherapy.
  • Chemotherapy was generally reserved for palliative cases; it can be now proposed as neoadjuvant treatment.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418930.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 18
  •  go-up   go-down


25. Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C: Esthesioneuroblastoma in Maffucci's syndrome. Skeletal Radiol; 2004 Oct;33(10):609-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 33-year-old man with Maffucci's syndrome who presented with a several month history of nasal congestion, facial pain, and diminished vision in his left eye.
  • Radiological studies showed a large soft tissue mass centered in the sinonasal area, extending bilaterally into maxillary sinuses and orbits with compression of left optic nerve.
  • Biopsy of the mass showed esthesioneuroblastoma (olfactory neuroblastoma).
  • Chemotherapy resulted in initial improvement, but the tumor recurred and did not respond to further treatment, resulting in his death.
  • [MeSH-major] Enchondromatosis / complications. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Arch Otolaryngol. 1979 Jul;105(7):427-30 [454301.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1169-77 [8073990.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):73-8 [7712654.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15221218.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Vasan NR, Medina JE, Canfield VA, Gillies EM: Sinonasal neuroendocrine carcinoma in association with SIADH. Head Neck; 2004 Jan;26(1):89-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroendocrine carcinoma (NEC) is a rare malignancy of the nasal cavity or paranasal sinuses.
  • After successful chemotherapy and radiotherapy treatment for the neoplasm, her SIADH resolved.
  • A literature search found eight cases of olfactory neuroblastoma (ONB) associated with SIADH, four of which resolved after treatment of the malignancy.
  • RESULTS: Treatment of the underlying malignancy resulted in the immediate resolution of the SIADH.
  • CONCLUSIONS: We report the first case of SIADH associated with NEC, which resolved after treatment of the cancer.
  • A direct cause and effect between ONB/nasal NEC and SIADH has been established in previous reports.
  • [MeSH-major] Carcinoma, Neuroendocrine / complications. Inappropriate ADH Syndrome / complications. Nasal Cavity. Nose Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 14724912.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Thompson LD, Wieneke JA, Miettinen M: Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system. Am J Surg Pathol; 2003 May;27(5):594-611
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients presented most frequently with epistaxis (n = 52), mass (n = 42), and/or nasal obstruction (n = 34) present for a mean of 8.2 months.
  • The majority of tumors involved the nasal cavity (n = 34), septum alone, or a combination of the nasal cavity and sinuses (n = 39) with a mean size of 2.4 cm.
  • Histologically, the tumors were composed of a variety of cell types (epithelioid, spindled, undifferentiated), frequently arranged in a peritheliomatous distribution (n = 39).
  • Immunohistochemical studies confirmed the diagnosis of sinonasal tract mucosal malignant melanomas with positive reactions for S-100 protein, tyrosinase, HMB-45, melan A, and microphthalmia transcription factor.
  • Sinonasal tract mucosal malignant melanomas need to be considered in the differential diagnosis of most sinonasal malignancies, particularly carcinoma, lymphoma, sarcoma, and olfactory neuroblastoma.
  • Surgery accompanied by radiation and/or chemotherapy was generally used.
  • The majority of patients developed a recurrence (n = 79), with 75 patients dying with disseminated disease (mean 2.3 years), whereas 40 patients are either alive or had died of unrelated causes (mean 13.9 years).
  • A TNM-type classification separated by anatomic site of involvement and metastatic disease is proposed to predict biologic behavior.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Mucosa. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12717245.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Koch M, Koester M, Schänzer A, Constantinidis J, Iro H: [Metastatic esthesioneuroblastoma. Challenge in interdisciplinary combined modality therapy]. HNO; 2002 Sep;50(9):853-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastatic esthesioneuroblastoma. Challenge in interdisciplinary combined modality therapy].
  • There is no standard therapy approach for these tumors.
  • The most widly accepted primary therapy is radical craniofacial enbloc resection followed by radiation therapy.
  • Today chemotherapy is getting more important and is administered with curative intention.
  • A clinical staging system as well as histopathological grading according of Hyams could be from importance for selection and timing of the different therapeutic modalities.
  • We present a case of a 34-year-old female patient who was diagnosed with an advanced olfactory neuroblastoma of the upper nasal cavity with bilateral cervical lymph node metastasis (modified Kadish-stage D).
  • Reviewing the recent literature the different therapeutic approaches are compared and discussed.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Lymphatic Metastasis / radiotherapy. Neck Dissection. Nose Neoplasms / surgery. Patient Care Team
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymphatic Irradiation. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Nose / pathology. Nose / surgery. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12425141.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Cackett P, Weir C: Olfactory neuroblastoma--an unusual presentation. J Neuroophthalmol; 2001 Jun;21(2):90-1
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma--an unusual presentation.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Biomarkers, Tumor / analysis. Diplopia / diagnosis. Diplopia / drug therapy. Exophthalmos / diagnosis. Exophthalmos / drug therapy. Female. Humans. Ifosfamide / therapeutic use. Infusions, Intravenous. Magnetic Resonance Imaging. Neurofilament Proteins / analysis. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis. Vision Disorders / diagnosis. Vision Disorders / drug therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450908.001).
  • [ISSN] 1070-8022
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Biomarkers, Tumor; 0 / Neurofilament Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement